CL2021000045A1 - Degradadores selectivos del receptor de estrógeno - Google Patents

Degradadores selectivos del receptor de estrógeno

Info

Publication number
CL2021000045A1
CL2021000045A1 CL2021000045A CL2021000045A CL2021000045A1 CL 2021000045 A1 CL2021000045 A1 CL 2021000045A1 CL 2021000045 A CL2021000045 A CL 2021000045A CL 2021000045 A CL2021000045 A CL 2021000045A CL 2021000045 A1 CL2021000045 A1 CL 2021000045A1
Authority
CL
Chile
Prior art keywords
estrogen receptor
selective estrogen
breakers
degradators
serds
Prior art date
Application number
CL2021000045A
Other languages
English (en)
Inventor
Jolie Anne Bastian
Jeffrey Daniel Cohen
Almudena Rubio
Daniel Jon Sall
Anne Mcmahon Jennifer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021000045(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2021000045A1 publication Critical patent/CL2021000045A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Finger-Pressure Massage (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

Se proporcionan novedosos degradadores selectivos del receptor de estrógeno (SERD) de acuerdo con la fórmula (I); sales aceptables desde el punto de vista farmacéutico de estos y composiciones farmacéuticas de estos, en donde ya sea R1 o R2 se selecciona independientemente de Cl, F, -CF3, o -CH3, y el otro es hidrógeno, y métodos para su uso.
CL2021000045A 2018-07-12 2021-01-07 Degradadores selectivos del receptor de estrógeno CL2021000045A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862697100P 2018-07-12 2018-07-12

Publications (1)

Publication Number Publication Date
CL2021000045A1 true CL2021000045A1 (es) 2021-07-19

Family

ID=67470734

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000045A CL2021000045A1 (es) 2018-07-12 2021-01-07 Degradadores selectivos del receptor de estrógeno

Country Status (36)

Country Link
US (4) US10654866B2 (es)
EP (2) EP4155310A1 (es)
JP (4) JP6995241B2 (es)
KR (3) KR102550538B1 (es)
CN (2) CN112638916B (es)
AR (1) AR115694A1 (es)
AU (2) AU2019299947B2 (es)
BR (2) BR112020025654A2 (es)
CA (1) CA3105501C (es)
CL (1) CL2021000045A1 (es)
CO (1) CO2021000043A2 (es)
CR (1) CR20210007A (es)
DK (1) DK3820873T3 (es)
EA (1) EA202092975A1 (es)
EC (1) ECSP21001770A (es)
ES (1) ES2933980T3 (es)
FI (1) FI3820873T3 (es)
HR (1) HRP20230009T1 (es)
HU (1) HUE060963T2 (es)
IL (3) IL280065B (es)
JO (1) JOP20210005A1 (es)
LT (1) LT3820873T (es)
MA (2) MA53124B1 (es)
MD (1) MD3820873T2 (es)
MX (2) MX2021000375A (es)
PE (1) PE20210400A1 (es)
PH (1) PH12021550049A1 (es)
PL (1) PL3820873T3 (es)
PT (1) PT3820873T (es)
RS (1) RS63809B1 (es)
SA (1) SA521421008B1 (es)
SG (1) SG11202100148TA (es)
SI (1) SI3820873T1 (es)
TW (1) TWI702219B (es)
UA (1) UA127507C2 (es)
WO (1) WO2020014435A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310489A (en) 2015-10-01 2024-03-01 Olema Pharmaceuticals Inc Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs and preparations containing them for use in cancer treatment
PL3820874T3 (pl) * 2018-07-12 2023-02-06 Eli Lilly And Company Selektywne środki degradujące receptor estrogenowy
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
CN114957114A (zh) * 2021-02-26 2022-08-30 冷志 一种4-溴-3-氯-7-甲氧基喹啉的合成方法
KR20230144571A (ko) 2021-03-09 2023-10-16 일라이 릴리 앤드 캄파니 Serd 투여 요법의 조합을 사용하여 암을 치료하는 방법
TW202300492A (zh) * 2021-03-16 2023-01-01 美商美國禮來大藥廠 選擇性雌激素受體降解劑
US11926634B2 (en) 2022-02-01 2024-03-12 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
WO2024097206A1 (en) 2022-11-02 2024-05-10 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004531562A (ja) * 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー ２−置換１，２，３，４−テトラヒドロキノリンおよびその誘導体、組成物ならびに方法
US7329654B2 (en) * 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
EP1497277A1 (en) * 2002-04-19 2005-01-19 Signal Pharmaceuticals, Inc. Benzopyranone compounds, compositions thereof, and methods of treatment therewith
US20090023917A1 (en) 2004-01-22 2009-01-22 Eli Lilly And Company Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
EP3010502B1 (en) 2013-06-19 2018-11-21 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
CN107406424B (zh) * 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
JP6679147B2 (ja) * 2014-12-18 2020-04-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロ−ピリド［３，４−ｂ］インドールエストロゲン受容体モジュレーター及びその使用
WO2018108954A1 (en) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
PL3820874T3 (pl) * 2018-07-12 2023-02-06 Eli Lilly And Company Selektywne środki degradujące receptor estrogenowy
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
FI3820873T3 (fi) 2023-03-02
HUE060963T2 (hu) 2023-04-28
SG11202100148TA (en) 2021-02-25
IL289871B2 (en) 2023-02-01
JP6995241B2 (ja) 2022-01-14
IL295598B1 (en) 2023-05-01
JP2022037102A (ja) 2022-03-08
IL289871B (en) 2022-10-01
US20230234960A1 (en) 2023-07-27
SI3820873T1 (sl) 2023-02-28
EP3820873B1 (en) 2022-11-23
IL295598B2 (en) 2023-09-01
JP7009672B1 (ja) 2022-01-25
KR20230005404A (ko) 2023-01-09
IL289871A (en) 2022-03-01
EP4155310A1 (en) 2023-03-29
AU2019299947B2 (en) 2022-03-17
MD3820873T2 (ro) 2023-05-31
UA127507C2 (uk) 2023-09-13
MX2021000375A (es) 2021-05-27
CA3105501A1 (en) 2020-01-16
MX2023006047A (es) 2023-06-02
US11993608B2 (en) 2024-05-28
CN112638916B (zh) 2023-09-12
TW202019935A (zh) 2020-06-01
PE20210400A1 (es) 2021-03-02
AU2022203969B2 (en) 2024-02-15
JP2022050591A (ja) 2022-03-30
JP7241211B2 (ja) 2023-03-16
MA53126B1 (fr) 2023-02-28
KR102589886B1 (ko) 2023-10-17
EA202092975A1 (ru) 2021-04-14
IL280065A (en) 2021-03-01
RS63809B1 (sr) 2023-01-31
AU2019299947A1 (en) 2021-01-07
DK3820873T3 (da) 2022-12-12
US20210403480A1 (en) 2021-12-30
KR20210019065A (ko) 2021-02-19
AU2022203969A1 (en) 2022-06-30
IL280065B (en) 2022-04-01
PL3820873T3 (pl) 2023-02-13
ECSP21001770A (es) 2021-02-26
PT3820873T (pt) 2022-12-23
HRP20230009T1 (hr) 2023-02-17
IL295598A (en) 2022-10-01
EP3820873A1 (en) 2021-05-19
SA521421008B1 (ar) 2022-10-30
MA53124A (fr) 2021-05-19
CA3105501C (en) 2023-10-31
PH12021550049A1 (en) 2021-09-20
MA53126A (fr) 2021-05-19
BR122023025061A2 (pt) 2024-02-20
CR20210007A (es) 2021-02-08
US10654866B2 (en) 2020-05-19
KR102550538B1 (ko) 2023-07-04
US20200347073A1 (en) 2020-11-05
JP2021530484A (ja) 2021-11-11
JOP20210005A1 (ar) 2021-01-10
MA53124B1 (fr) 2023-02-28
US11117902B2 (en) 2021-09-14
ES2933980T3 (es) 2023-02-15
US11634426B2 (en) 2023-04-25
KR20230148386A (ko) 2023-10-24
LT3820873T (lt) 2023-01-10
AR115694A1 (es) 2021-02-17
CN112638916A (zh) 2021-04-09
TWI702219B (zh) 2020-08-21
WO2020014435A1 (en) 2020-01-16
US20200017516A1 (en) 2020-01-16
CN117379428A (zh) 2024-01-12
JP2023081954A (ja) 2023-06-13
BR112020025654A2 (pt) 2021-04-06
CO2021000043A2 (es) 2021-01-18

Similar Documents

Publication Publication Date Title
CL2021000045A1 (es) Degradadores selectivos del receptor de estrógeno
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2021000046A1 (es) Degradadores selectivos del receptor de estrógeno
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
BR112019005595A2 (pt) compostos e métodos para modulação de ido e tdo, e indicações para os mesmos
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
AR049708A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AR049706A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
PE20190258A1 (es) Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
MX2021004000A (es) Derivados de piperidina.
AR045900A1 (es) Compuesto glucocorticoesteroide, composiciones farmaceuticas que los contienen y su uso para el tratamiento de trastornos inflamatorios y/o alergicos.
CL2018003121A1 (es) Inhibidores del potenciador del homólogo zeste 2.
CR20190379A (es) Moduladores del receptor de estrógeno
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
BR112014008312A2 (pt) aditivos para cimento e métodos relacionados de uso
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
UY35536A (es) ?derivados de sulfonamida?.
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR106981A1 (es) Una composición antimicrobiana
AR125059A1 (es) Degradadores selectivos del receptor de estrógeno
PE20181053A1 (es) Compuestos, composicion farmaceutica y su uso en el tratamiento de enfermedades neurodegenerativas
AR113100A1 (es) Compuestos que activan la ruta nrf2